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ABSTRACT
Background. Randomized clinical trials (RCTs) can pro-
vide a high level of evidence for medical decision making,
but it is unclear if the results apply to patients treated
outside such trials.
Objective. The aim of this study was to retrospectively
compare outcomes of patients with esophageal cancer
treated within and outside an RCT.
Methods. All patients receiving neoadjuvant chemora-
diotherapy (nCRT) plus surgery for esophageal cancer
between 2002 and 2008 (ChemoRadiotherapy for Eso-
phageal cancer followed by Surgery Study [CROSS]
cohort) who participated in multicenter, phase II–III trials
were compared with patients who underwent the same
treatment outside the trial between 2008 and 2013 (post-
CROSS cohort). The differences between these cohorts
were analyzed using t tests, while logistic regression
models were used to evaluate adverse events. Overall and
disease-free survival were calculated using the Kaplan–
Meier method and Cox regression analyses.
Results. A total of 208 CROSS patients and 173 post-
CROSS patients were included in this study. Patients from
the post-CROSS cohort were older, had more co morbidi-
ties, and had poorer performance status. Clinical N stage,
but not cT stage, was worse in the post-CROSS cohort.
There were no statistically significant differences in
adverse events (pulmonary, cardiac, or anastomotic com-
plications) or survival between the comparison cohorts.
Conclusion. The outcomes of patients treated with nCRT
plus esophagectomy for cancer have a high external con-
sistency and can be extrapolated to the daily practice of
physicians involved in the treatment and care of esophageal
cancer patients.
Randomized clinical trials (RCTs) can provide high
levels of evidence for treatment efficiency in medicine;1, 2
however, RCTs often have strict inclusion and exclusion
criteria, which might limit the generalizability of an RCT
to a target population. The effectiveness and safety of
treatment for a patient who does not match the eligibility
criteria of trial participants is unclear.
Participation in an RCT, especially in the treatment arm,
can be beneficial to patients.3 It is suggested that better care
and closer and more frequent follow-up of trial participants
might lead to better outcomes than in non-participants.
Studies that have evaluated this question report mixed
results.4–7
The ChemoRadiotherapy for Esophageal cancer fol-
lowed by Surgery Study (CROSS) is an RCT that
compared outcomes after neoadjuvant chemoradiotherapy
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(nCRT) plus surgery with surgery alone in patients with
esophageal cancer.8–10 This study, as well as a meta-anal-
ysis, showed an improved survival of patients treated with
nCRT.11 Hence, multimodality treatment is now consid-
ered standard of care for patients with
resectable esophageal cancer. However, little is known
about the selection and outcomes of patients receiving
nCRT plus surgery in the setting of standard of care
compared with patients who participated in the CROSS
trial.
The aim of this study was to compare the patient char-
acteristics and outcomes of CROSS study participants with
patients who underwent nCRT plus surgery outside the
study to evaluate whether outcomes remain similar.
METHODS
Patients
Patients with histologically proven esophageal cancer
who participated in the CROSS I and II studies that ran
between February 2001 and January 2004 (CROSS I) and
March 2004 through December 2008 (CROSS II) were
defined as the CROSS cohort.8,9 Eight centers in The
Netherlands participated in the CROSS trial. Inclusion and
exclusion criteria have been reported previously.9,10 All
patients with a resectable esophageal cancer (cT1N1 or
T2–T4a, N0–N3, M0 tumor) and who were fit for nCRT
plus surgery, as judged by the surgeon responsible, medical
oncologist, and radiation oncologist between July 2008 and
December 2013, were eligible for the post-CROSS cohort.
These patients were all treated within the Erasmus MC.
After the closure of patient recruitment for the CROSS
trial, and before final publication of the full paper, the
multidisciplinary team at the Erasmus MC had already
considered nCRT as standard treatment based on system-
atic reviews. Hence, patients were treated from 2008
onwards outside the study protocol. These patients were
identified from an institutional database (Erasmus MC –
University Medical Centre Rotterdam). Ethical approval
was not applicable because of the retrospective design of
the study, as judged by the Ethical Committee of the
Erasmus MC.
Staging
All participating patients underwent history taking,
physical examination, and routine hematological and bio-
chemical tests. The standard tumor staging procedures
included an upper gastrointestinal endoscopy with biopsies,
endoscopic ultrasonography (EUS), and computerized
tomography (CT) of the neck, chest and abdomen. EUS-
guided fine-needle aspiration (FNA) was performed only
when indicated; external ultrasonography of the neck, with
FNA in case of suspected metastatic lymph nodes, and
bronchoscopy and positron emission tomography (PET),
were used in selected patients only. Only in T3 tumors was
PET of any additional value at that time, and, in addition,
was not yet standardized. Tumors were staged according to
the tumor node metastasis (TNM) classification of the
International Union Against Cancer 7th UICC-AJCC TNM
staging manual.12
Neoadjuvant Chemoradiotherapy
nCRT was administered within 5 weeks after comple-
tion of tumor staging and after discussion at the
multidisciplinary team meeting. On days 1, 8, 15, 22, and
29, carboplatin and paclitaxel (targeted at an area under the
curve of 2 mg/mL/min and at a dose of 50 mg/m2 of body
surface area, respectively) were administered intra-
venously. Concurrently, external radiation was
administered at a dose of up to 41.4 Gy in 23 fractions of
1.8 Gy each, with five fractions administered per week,
starting on the first day of the first chemotherapy cycle.
Surgery
For tumors involving the gastroesophageal junction, or
in patients with a poor performance status (WHO perfor-
mance score of 2 or higher), a transhiatal resection was
preferred.13,14 A transthoracic approach with two-field
lymph node dissection was mostly performed for tumors of
the intrathoracic esophagus and for junctional tumors with
positive lymph nodes at or above the carina. Dissection of
the nodes along the celiac axis and its branches was per-
formed in both approaches. A gastric tube reconstruction
with cervical anastomosis was the preferred technique for
restoring the continuity of the digestive tract. A minimally
invasive approach was introduced in 2010, i.e. a thoraco-
laparoscopic esophagectomy (McKeown procedure)
performed by a single surgeon. Lymph node dissection was
similar to the open technique. An open left thoracoab-
dominal approach was used in some patients as part of a
training program under the guidance of a teaching surgeon,
and the resection specimen was evaluated for residual
disease. Irradicality of the tumor resection margins (R1)
was defined as vital tumor cells within 1 mm of the
resection margins (proximal, distal and/or circumferential),
and a pathologically complete response was defined as no
vital tumor cells left in the resection specimen
(ypT0N0M0), according to a modified Mandard score
system.15,16
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Complications were carefully registered for both
cohorts; it is common sense to provide these data to the
Dutch Upper GI Cancer Audit (DUCA).
Follow-Up
All patients were seen in the outpatient clinic at least
every 3 months during the first year after surgery and every
6 months during the second year, and were followed at
least once a year in years 3, 4, and 5 after surgery. CT of
the neck, chest and abdomen was only performed when a
recurrence was clinically suspected.
Statistical Analysis
Differences in patient characteristics between the com-
parison cohorts were assessed using the Student t test or
Chi square test. When there were more than two categories
within a parameter, a Chi square test for trend was used.
The occurrence of adverse events was presented as fre-
quencies, and differences in frequencies between the
cohorts were calculated using the t test and presented as
p values, with 5% as the level of statistical significance.
Additionally, the odds of an occurrence of an adverse event
in the two cohorts were calculated using univariable and
multivariable logistic regression and presented as odds
ratios (ORs) with 95% confidence intervals (CIs), and
p values. The multivariable regression model included
adjustment for potential confounding by age (continuous
variable), sex, surgical approach (transhiatal or transtho-
racic), and tumor stage (categorized according to the 7th
TNM classification Ia, Ib, IIa, IIb, IIIa–IIIb, IIIc and IV).
The probability of survival over time was estimated using
the Kaplan–Meier method, and the log-rank test was used
to assess differences between the cohorts. All patients were
updated in July 2016 with regard to date of recurrence,
survival, and last day of follow-up. To determine variables
that affected survival, a Cox regression model was used to
calculate hazard ratios (HRs) with 95% CIs, with adjust-
ment for age, sex, surgical approach, complications
(categorized as any or none), and tumor stage.
RESULTS
Patients
A total of 208 patients (51 from CROSS I and 157 from
CROSS II) were included in the CROSS cohort, while the
post-CROSS cohort consisted of 173 patients. Patients in
the post-CROSS cohort were older and had more comor-
bidities and poorer performance status. In addition, clinical
N stage, but not cT stage, was worse in the post-CROSS
cohort (Table 1).
Fourteen patients who underwent nCRT did not proceed
to surgery because of poor general condition or as a result
of the patient’s own decision. In another 19 patients, distant
dissemination was present at surgical exploration or the
primary tumor or lymph nodes found could not be resected.
These patients were excluded from the final analyses.
Treatment Characteristics and Pathology
More than 95% of patients in each cohort finished all
five cycles of neoadjuvant chemotherapy and 23 fractions
of radiotherapy, and there were no statistically significant
differences in completion rate between the cohorts
(p = 0.348 and p = 0.196, respectively). The mean (stan-
dard deviation) time between the end of nCRT and surgery
was 6.6 weeks (0.1) for the CROSS cohort and 7.9 weeks
(0.3) for the post-CROSS cohort (p\ 0.001) (Table 2).
Pathological tumor stage was not statistically significantly
different between the cohorts (p = 0.76). The percentage of
patients with complete pathological response (ypT0N0M0)
was 27% (n = 56) in the CROSS cohort and 28% (n = 49)
in the post-CROSS cohort (p = 0.76).
Adverse Events
There were no statistically significant differences in
adverse events (pulmonary, cardiac, or anastomotic com-
plications) between the cohorts, except for chylothorax (see
electronic supplementary material). The OR of infectious
complications was increased in the post-CROSS cohort
compared with the CROSS cohort (OR 1.88, 95% CI
0.99–3.58, p = 0.054), but the difference was not statisti-
cally significant (electronic supplementary material).
Survival
Median overall survival was 44.2 months (interquartile
range [IQR] 15.2–64.9); median overall survival in the
CROSS cohort was 58.5 months (IQR 19.0–86.8) versus
35.0 months (IQR 12.9–51.4) in the post-CROSS cohort
(95% CI 16.1–29.4).
The HRs of mortality were similar when comparing
cohorts for overall survival, 30- and 90-day mortality, and
disease-free survival (Table 3). Overall 5-year survival and
5-year disease-free survival were not statistically signifi-
cantly different between the CROSS and post-CROSS
cohorts (log-rank 0.90, overall 95% CI 39.2–43.8; and log-
rank 0.69, overall 95% CI 39.6–44.5, respectively)
(Figs. 1, 2).
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DISCUSSION
This study shows similar survival rates in patients
included in the CROSS trial and those treated after the
RCT, after adjustment for confounders. Those who
underwent nCRT plus surgery outside the CROSS trial
were older and had more comorbidities and a poorer per-
formance status. In addition, more patients with T1 tumors,
as well as patients with extensive nodal disease (cN3
stage), underwent multimodality treatment as the inclusion
criteria of the CROSS trial excluded these patients. This
may indicate that the multidisciplinary team has become
more liberal in selecting patients for nCRT, given the
confirmed effectiveness of this treatment.9,10
The poorer performance status of patients in the post-
CROSS cohort did not translate into a decreased tolerance
to nCRT. In both cohorts, more than 95% of patients
completed the treatment and went on to have surgery. The
TABLE 1 Patient and tumor
characteristics of 381 patients,
divided into the CROSS
(n = 208) and post-CROSS
(n = 173) cohorts for patients
with oesophageal or junctional
cancer who underwent
neoadjuvant chemoradiotherapy
according to CROSS followed
by surgery
CROSS Post-CROSS
N (%) N (%) p value
Total 208 173
Age, years Mean [SD] 60 [0.8] 62 [0.7] 0.004
\60 107 (51) 62 (36) 0.001
60–65 37(18) 36 (21)
66–69 35 (17) 33 (19)
70–75 27 (13) 28 (16)
[ 75 2 (1) 14 (8)
Sex Male 163 (78) 137 (79) 0.8
Female 45 (22) 36 (21)
Comorbidity No 162 (78) 113 (65) 0.002
One or more 46 (22) 60 (35)
Charlson index 0 162 (78) 110 (64) 0.007
1 40 (19) 48 (28)
2 6 (3) 14 (8)
3
Karnofsky performance status 60 1 (0) 0 (0) 0.000
70 2 (1) 0 (0)
80 9 (4) 16 (9)
90 90 (44) 126 (73)
100 73 (35) 8 (5)
Missing 33 (16) 23 (13)
Tumor length, cm Mean [SD] 4.5 [0.15] 5.1 [0.19] 0.008
B 8 183 (86) 154 (91)
[ 8 7 (4) 16 (9) 0.02
Missing 18 (9) 3 (2)
Clinical T stage T1 1 (0) 9 (5) 0.04
T2 30 (14) 37 (21)
T3 176 (85) 115 (66)
T4 0 (0) 8 (5)
Missing 1 (0) 4 (2)
Clinical N stage N0 78 (37) 53 (31) 0.000
N1 114 (55) 54 (31)
N2 13 (6) 55 (31)
N3 2 (1) 8 (4)
Missing 1 (0) 3 (2)
Histology Adenocarcinoma 160 (77) 133 (76) 0.5
Squamous cell carcinoma 48 (23) 40 (23)
CROSS ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study, SD standard deviation
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toxicity profile of the CROSS regimen is favorable com-
pared with other neoadjuvant regimens, including the
MAGIC regimen and 5-fluorouracil/cisplatin combina-
tion.8,17 This could have also played a role in the decision
of the multidisciplinary team to also recommend nCRT for
older and frail patients.18 Age alone is not considered an
absolute contraindication for surgery with or without
neoadjuvant treatment.
Overall survival and disease-free survival were not sta-
tistically significantly different between the cohorts. In
addition, postoperative complications did not differ,
despite the small difference in comorbidity and perfor-
mance status of the cohorts. A non-significantly higher
percentage of patients in the post-CROSS cohort under-
went a transthoracic resection, which did not seem to
translate into more pulmonary or cardiac complications, as
TABLE 2 Details on treatment regimen and pathological assessment
of the resection specimen of 381 patients, divided into the CROSS
(n = 208) and post-CROSS (n = 173) cohorts for patients with
oesophageal or junctional cancer who underwent chemoradiotherapy
according to CROSS followed by surgery
CROSS Post-CROSS
N (%) N (%) p value
Total 208 173
Chemotherapy \ 5 cycles 4 (2) 6 (4) 0.348
5 cycles 204 (98) 167 (96)
Radiotherapy \ 23 cycles 2 (1) 0 (0) 0.196
23 cycles 206 (99) 173 (100)
Weeks between end of nCRT and surgery Mean [SD] 6.6 [0.1] 7.9 [0.3] \ 0.001
B 6 95 (46) 48 (28) \ 0.0001
[ 6 113 (54) 125 (72)
Surgical approach Transthoracic 92 (44) 89 (52) 0.734
Transhiatal 116(56) 56 (33)
Othera 0 (0) 28 (16)
Resection margins R0 195 (94) 159 (92) 0.486
R1 13 (6) 14 (8)
ypT stageb T0 71 (34) 57 (33) 0.65
T1 29 (14) 25 (14)
T2 41 (20) 30 (17)
T3 64 (31) 60 (35)
T4 2 (1) 1 (1)
Missing 1 (0) 0 (0)
ypN stageb N0 144 (69) 108 (62) 0.22
N1 45 (22) 51 (29)
N2 15 (7) 9 (5)
N3 4 (2) 5 (3)
LN ratio Mean [SD] 0.065 [0.142] 0.046 [0.092] \ 0.0001
Pathological complete responsec T0N0M0 56 (27) 49 (28) 0.76
Differentiation grade Poor 26 (12) 53 (31) \ 0.0001
Moderate 26 (12) 49 (28)
Good 1 (1) 3 (2)
Unknown, including pCR 155 (75) 68 (40)
CROSS ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study, nCRT neoadjuvant chemoradiotherapy, SD standard deviation,
R0 tumor-free resection margin, R1 tumor cells within 1 mm or at the resection margin, ypT stage T stage after nCRT, ypN stage N stage after
nCRT, pCR pathologically complete response, LN ratio ratio of positive/resected lymph nodes divided by the number of resected lymph nodes
(between 0 and 1)
aOther approaches, including minimally invasive esophagectomy and left thoracoabdominal approach
bPathological T and N stage after neoadjuvant chemoradiotherapy
cPathologically complete response (ypT0N0M0)
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has been previously reported.13,18 Pathological tumor stage
was also not significantly different between the cohorts,
which supports a high efficacy of the multimodal treatment
that persisted in the years after the trial finished. Since the
publication of the CROSS study, nCRT is used by more
institutes in the Southwest of the Netherlands, including
centers that refer patients to the Erasmus MC for surgery.
The fact that a pathologically complete response is
obtained in a large percentage of patients in the post-
CROSS cohort is indicative of the sustained efficacy of the
chemoradiotherapy treatment.
The time to surgery after finishing nCRT was somewhat
longer for the post-CROSS cohort, which reflects logistic
problems in the center and a less-stringent planning of the
operation, as is usually dictated by a study protocol. A
longer time to surgery may affect pathological staging but
might not impact on survival, as shown in the present
study.19
Enrolment in RCTs may lead to better outcomes in
patients with cancer. In chronic myelocytic leukemia, the
survival rate of patients within clinical trials was higher
than patients outside trials.20 An explanation for this could
be the access to better medications and, in particular, the
selection of healthier patients for trials. In a recent paper on
surgery for a benign upper gastrointestinal disease, trial
participation did not affect clinical outcome.4
One of the limitations of this present study is that the
post-CROSS cohort was retrospectively evaluated, which
may have introduced bias and incomplete reporting of
outcome parameters, including complications such as tox-
icity of the nCRT; increased toxicity in elderly patients
with poorer performance status and more comorbidity may
have been missed. However, overall survival and mortality
are unambiguous endpoints. It should be noted that follow-
up of the post-CROSS cohort was not as long as the
CROSS cohort. Nevertheless, the recurrence of esophageal
TABLE 3 Hazard ratios for mortality comparing patients who
underwent CROSS inside a trial (reference) with patients treated in
the post-CROSS era
HR 95% CI p value
30-day mortality 1.37 0.40–4.68 0.62
90-day mortality 0.53 0.23–1.25 0.15
Overall survival 1.02 0.75–1.39 0.90
Disease-free survival 0.93 0.67–1.31 0.69
CROSS ChemoRadiotherapy for Oesophageal cancer followed by
Surgery Study, HR hazard ratio, CI confidence interval
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cancer typically occurs within 2 years of surgery and most
patients were followed up for more than 24 months.
Changes in surgical techniques (minimally invasive tech-
niques) and perioperative patient management could, to
some extent, have influenced outcomes in favor of the post-
CROSS cohort. Moreover, selection bias could have
occurred since patients who did not receive nCRT in the
years after publication of the CROSS study could not be
identified.
Another weakness of this study is that both cohorts may
not be completely similar due to the fact that the CROSS
cohort, acting as the control, was derived from a random-
ized controlled trial, wherein a variety of hospitals
participated. The post-CROSS cohort was identified, in
retrospect, from a single tertiary referral center (also par-
ticipating in the original CROSS study). Furthermore, the
inclusion criteria for patients receiving nCRT were
expanded on. Although no formal changes in the periop-
erative care protocol (e.g. enhanced recovery program)
took place at the Erasmus MC during the study period,
minor changes in perioperative care, field planning for
radiotherapy, and time between the end of nCRT and
surgery may have occurred, with a (small) impact on the
(short-term) outcomes reported in this study,18,21 It is
unlikely that overall survival, the main outcome measure of
this study, is affected by these factors. Finally, some
tumors could not be restaged retrospectively from the TNM
6th edition (CROSS I and II) to the TNM 7th edition,12
which may have had a small impact on the CROSS cohort
in relation to N stage.
When the inclusion criteria of the CROSS trial were
projected onto the patients of the post-CROSS cohort, 14
patients did not qualify for nCRT due to older age, and 19
patients had a tumor length of[ 8 cm. Despite this find-
ing, it is felt that while there are differences in patient and
tumor characteristics between the two cohorts, it is safe to
apply nCRT to most patients with a resectable esophageal
cancer who have been evaluated and discussed in a mul-
tidisciplinary team. In these patients, the benefit in survival
and harm of the multimodal treatment is likely within the
same range, as reported in patients participating in the
CROSS trial.
CONCLUSION
The outcomes of patients treated with nCRT plus
esophagectomy for esophageal cancer have a high external
consistency and can possibly be extrapolated to the daily
practice of physicians involved in the treatment and care of
esophageal cancer patients.
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